Drug Trial Radar · NCT02373280
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Aug 2014
Primary completion
Apr 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Seoul National University Bundang HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 27, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
Conditions
- Helicobacter Infection
Interventions
10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)Drug
In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)Drug
the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]
7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]Drug
moxifloxacin triple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)\].
7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)Drug
bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the percentage of participants with successful H. pylori eradication in each groupsTime frame: 6 weeks after completion of eradication
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.